Fundraising Fox

Exevir

Ghent, BE · 6 known investors

Find your way into Exevir

ExeVir develops multi-specific VHH antibody therapies to treat infectious diseases, immunological conditions, and oncology, with a focus on immunocompromised populations. The company operates as a clinical-stage biotech firm leveraging a modular antibody platform to accelerate drug development.

BiotechDeep TechDigital HealthHealthtechMedical Devices

Founders & leadership

XS
Xavier SaelensScientific Founder
NC
Nico CallewaertinScientific Founder
MG
Mike GarrettChief Executive Officer

Investors · 6

V-Bio Ventures✓ verifiedGhent · $270K – $2.2M
Sambrinvest✓ verifiedCharleroi
UCB Ventures✓ verifiedBrussels
VIB✓ verifiedGhent
Fund+Leuven · $5.5M – $16.5M
VIVES PartnersWavre · $108K – $7.6M

Frequently asked questions

What does Exevir do?
ExeVir develops multi-specific VHH antibody therapies to treat infectious diseases, immunological conditions, and oncology, with a focus on immunocompromised populations. The company operates as a clinical-stage biotech firm leveraging a modular antibody platform to accelerate drug development.
Who founded Exevir?
Exevir was founded by Xavier Saelens, Nico Callewaert.
Who are Exevir's investors?
Exevir's investors include V-Bio Ventures, Sambrinvest, UCB Ventures, VIB, Fund+, VIVES Partners.
Where is Exevir headquartered?
Exevir is headquartered in Ghent, BE.